ClinicalTrials.gg

Program

TQB2922

A development code. Also written as “TQB2922 injection (subcutaneous administration)”, “TQB2922 injection (subcutaneous injection)” and “TQB2922 Subcutaneous Injection”.

In Sino Biopharmaceutical's pipeline, EGFR/cMET双抗. Its studies are mostly in Colorectal Neoplasms · Head and Neck Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 2, since Jun 23, 20255 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical55 open or runningphase 2since Jun 23, 2025Dec 19, 2023Dec 2026phase 1 · NCT06188624
  • Named in Sino Biopharmaceutical’s own pipeline as TQB2922, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2023First study: phase 1 study in Advanced CancerFirst studyNCT06188624 · 150 planned · China
  2. Jun 23, 2025Phase 2 study in RAS/BRAF Wild Type Colorectal CancerNCT07044908 · 72 planned · China
  3. Nov 20, 2025Phase 1 study in Advanced CancersNCT07260708 · 42 planned · China
  4. May 17, 2026Phase 2 study in Head and Neck NeoplasmsNCT07601204 · 128 planned · China
  5. Sep 16, 2026Phase 2 study in Colorectal NeoplasmsNCT07844187 · 64 planned · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in Advanced CancerNCT06188624
  2. Aug 31, 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07844187
  3. Feb 2029Primary completion: phase 2 study in Head and Neck NeoplasmsNCT07601204
  4. Dec 2029Primary completion: phase 1 study in Advanced CancersNCT07260708

TargetBeta

“EGFR/cMET双抗”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
amivantamabruleJohnson & Johnsonphase 316
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
pamvatamigruleBetta Pharmaceuticalsphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07844187Colorectal Neoplasms · China2Not yet recruitingAug 31, 202764
NCT07601204Head and Neck Neoplasms · China2Not yet recruitingFeb 2029128
NCT07260708Advanced Cancers · China1RecruitingDec 202942
NCT07044908RAS/BRAF Wild Type Colorectal Cancer · China2RecruitingJul 202672
NCT06188624Advanced Cancer · China1RecruitingDec 2026150

How it is read

Names in the registry

  • “TQB2922 injection (subcutaneous administration)”, 1 entry
  • “TQB2922 injection (subcutaneous injection)”, 1 entry
  • “TQB2922 Subcutaneous Injection”, 1 entry
  • “TQB2922 injection ± TAS-102 tablets”, 1 entry
  • “TQB2922 injection+TAS-102 tablets ± Bevacizumab”, 1 entry

Codes read as this program: TQB2922.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.